Cognitive Remediation as a Tool for Enhancing Treatment Dimensions of Schizophrenic Symptomatology: A Systematic Review of Randomized Controlled Trials
Maria Skokou, Panagiotis-Diogenis Stavridis, Aikaterini Ntoskou-Messini, Lambros Messinis

TL;DR
This review examines how cognitive remediation affects different symptoms of schizophrenia, finding it most effective for negative symptoms but with mixed results for others.
Contribution
The paper systematically reviews randomized controlled trials to clarify the effectiveness of cognitive remediation across various symptom dimensions in schizophrenia.
Findings
Cognitive remediation consistently improves negative symptoms of schizophrenia.
Effects on positive symptoms correlate with baseline severity.
Results for mood and anxiety symptoms are contradictory across studies.
Abstract
Background/Objectives: Despite efforts, schizophrenia remains a difficult disease to treat for cognitive, positive, negative, and mood symptoms. In the present review, we explore existing data on the ameliorating effects of neurocognitive rehabilitation and the diverse symptomatology of the disorder. Methods: This systematic review has been registered with PROSPERO (registration number: CRD 420251154674). Following PRISMA guidelines, we conducted a search in PubMed, Scopus, and Science Direct database from inception to 14 July 2025. The methodological quality assessment was made by applying the Joanna Briggs Institute (JBI) critical appraisal tool for systematic reviews. Results: Of the 1001 records screened for eligibility, thirty-five studies were identified for data extraction and synthesis. Of these, seven had a low risk of bias, and seven had a high bias risk. The effects of…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1| Study | Country | Sample (Training/Control, Age, % Males, Setting) | Type of Intervention | Study Duration and Dose | Cognitive Functions Targeted | Control Group | Results | Risk of Bias |
|---|---|---|---|---|---|---|---|---|
| Gharaeipour and Scott, 2012 | Iran | Cognitive remediation | 1 h/session, | Attention, working memory, executive functions | Group supportive therapy | No significant differences in PANSS, BDI, BAI | Moderate | |
| Zhu et al., 2021 [ | China | Compensatory Cognitive Training combined with Medication Self-Management Skills Training; | CCT: 2 h/session, | Prospective memory, | Treatment as Usual (psychopharmacological therapy) | Significant group × time interaction for CCT + MSST compared with TAU in PANSS positive symptoms (MD = −0.101, | Moderate | |
| Vita et al., 2011b | Italy | Integrated Psychological Therapy (IPT) | 45 min/session, | Attention (selective and sustained), | Treatment as Usual (psychopharmacological therapy) | Significant difference on PANSS total score (IPT: 95.8 ± 14.4 → 66.7 ± 11.5; control: 94.0 ± 11.7 → 77.8 ± 14.9, | Moderate | |
| Penadés et al., 2006 | Spain | Cognitive remediation therapy | 1 h/session, | Flexibility in thinking and information set maintenance, | CBT, | Significant difference for the PANSS depression items (CBT: 10.9 ± 3.0 → 6.6 ± 1.9; CRT: 10.3 ± 3.3 → 116 ± 3.4); no significant differences for other subscales | Low | |
| Vita et al., 2011a | Italy | Integrated Psychological Therapy–Cognitive Remediation; | 45 min/session, 2 sessions/w, | IPT-Cog: cognitive differentiation, social perception, verbal communication, social skills, and interpersonal problem solving; | Rehabilitation: | Significant differences between groups in CGI-S | Low | |
| Zhu et al., 2022 | China | Computerized cognitive remediation therapy; | 45 min/session, | Cognitive flexibility, working memory and planning, | Active control: dance learning, playing a simple instrument | No significant effects on PANSS scores | Low | |
| Zhu et al., 2020 | China | Computerized cognitive remediation therapy | 45 min/session, | Cognitive flexibility, working | Treatment as Usual | No significant effects on PANSS scores | Moderate | |
| Tan et al., 2016 | China | Group cognitive remediation therapy, | 1 h/session, | Flexibility in thinking and | Musical and Dancing Therapy (MDT) | No significant effect on PANSS scores | Low | |
| D’Amato et al., 2011 | France | Cognitive remediation therapy, Rehacom | 2 h/session, | Attention/ | Treatment as Usual, | No significant effect on PANSS, CGI scores | High | |
| Ricarte et al., 2012 | Spain | Event-Specific Memory Training | 90 min/session, | Autobiographical memory | Social skills and occupational therapy | Significant differences between groups for BDI scores (experiment: 18.25 ± 12.3 → 10.16 ± 8.4; control: 12.42 ± 10.2 → 11.92 ± 11.0, | Moderate | |
| Omiya et al., 2016 | Japan | Frontal/Executive | 60 min/session, | Cognitive flexibility, working memory, planning | Treatment as Usual (psychopharmacological therapy) | Significant differences for PANSS total scores (FEP: 79.9 ± 7.9 → 68 ± 10.2; control 77.4 ± 6.2 → 78.1 ± 7.59, | Low | |
| Wykes et al., 2007 | U.K. | Cognitive remediation therapy | 1 h/session, | Memory, | Treatment as Usual (psychopharmacological therapy) | No significant effect on SPRS | Moderate | |
| Rakitzi et al., 2016 | Integrated | 1 h/session, | Vigilance/attention, | Treatment as Usual (psychopharmacological) | Significant differences between groups for PANSS negative scores | Moderate | ||
| Wykes et al., 2003 | U.K. | Cognitive remediation therapy | 12 weeks | Flexibility, memory, | Intensive occupational therapy activities | No significant effect on BPRS scores | Moderate | |
| Sachs et al., 2012 | Austria | Training of Affect Recognition (TAR) | 2 sessions/w, | Facial affect recognition | Treatment as Usual, occupational therapy | Significant within-group differences for PANSS negative scores | High | |
| Giuliani et al., 2024 | Italy | Modified Social Cognition Individualized Activities | 30 min/session, | Social cognition | Treatment as Usual (pharmacological, psychological, rehabilitative, occupational) | No significant effect on PANSS scores | High | |
| Li et al., 2022 | China | Virtual reality (VR) | 5 sessions/w, | Working memory, | Treatment as Usual | Significant pre and post differences for PANSS general scores | Moderate | |
| Fathi et al., 2025 | Iran | Computerized Cognitive | 1 h/session, | Spatial Recognition Memory (SRM), Paired | Active control: | Significant main effects of time and time × group interaction on DASS-D scores (CCT: MD = −1.85, 95% CI [−1.90, 0.42], | Low | |
| Zhang et al., 2024 | China | Computerized cognitive remediation therapy | 40 min/session, | Attention, | Treatment as Usual | Significant time × group interaction for PANSS total scores (CCRT: 77.30 ± 2.68 vs. 75.90 ± 2.72 vs. 74.90 ± 2.85; control: 80.90 ± 2.11 vs. 80.90 ± 2.11 vs. 80.90 ± 2.11, | High | |
| Dai et al., 2022 | China | Computerized cognitive remediation therapy; CCRT + aerobic exercise = CAE | 30 min/session, | Processing speed, | Aerobic, | Significant pre and post differences for PANSS negative scores | Moderate | |
| Fekete et al., 2022 | Hungary | Group Metacognitive Training (MCT) | 1 session/w, | Mental flexibility, | Treatment as Usual (psychopharmacological | PANSS between groups post intervention | Moderate | |
| Sampedro et al., 2021 | Spain | Rehacop + | 60 min/session, 3 sessions/w, | Attention, visual and verbal learning, recall, recognition memory, working memory; | Active control, | Significant pre and post differences for negative scores | Moderate | |
| Rocha et al., 2021 | Portugal | Group Social Cognition and Interaction Training (SCIT) | 45–60 min/ session, | Theory of Mind, | Psychoeducation | No significant effect on PSP or PANSS scores | Moderate | |
| Bossert et al., 2020 | Germany | Group Computer-Assisted Cognitive Remediation CogniPlus (I-CACR); Individualized | 50 min/session, | Attention: alertness, selective, divided; working memory, executive functions | Treatment as Usual (pharmacological and psychotherapeutic treatment, | No significant effect on PANSS or HAMD scores, except for | Moderate | |
| Matsuda et al., 2018 | Japan | Japanese Cognitive Rehabilitation Program | 60 min/session, | Attention, psychomotor speed, learning, memory, executive functions | Treatment as Usual, waiting list | Significant differences between groups for PANSS on PANSS general subscales (JCORES: −3.17 ± 4.33; control: −0.06 ± 5.93, | Moderate | |
| Peña et al., 2016 | Spain | Rehacop | 90 min/session, | Attention: sustained, selective, alternating, divided; | Occupational group activities | Significant effect on PANSS negative scores | Moderate | |
| Cella et al., 2014 | U.K. | Cognitive rehabilitation | 3 sessions/w, | Executive functions, working memory, long-term memory, attention | Treatment as Usual (psychopharmacological therapy) | Significant reduction of negative symptoms and disorganization in the CR group: | Moderate | |
| Klingberg et al., 2011 | Germany | 198 | Cognitive rehabilitation, restitution, compensation of cognitive deficits | 47.5 min/session (mean), 13.7 sessions | Attention, memory, executive functions | CBT | No significant effect on PANSS, SANS, CDSS, or CGI scores | Low |
| Kayser et al., 2006 | France | 14 | Theory of Mind Training using videos depicting emotional interactions | 1 session/w, | Theory of Mind | Treatment as Usual (psychopharmacological therapy) | No significant effects on PANSS and BPRS scores | High |
| Reeder et al., 2004 | U.K. | 31 | Cognitive rehabilitation training | 3 sessions/w, | Attention, memory; executive functions: cognitive shift, working memory, planning | Occupational therapy, activities to account for therapist contact | No significant effects on BPRS scores | High |
| Beigi et al., 2008 | Iran | 42 | Cognitive rehabilitation therapy | 30–45 min/session, | Attention, memory, executive function, abstract thinking | Treatment as Usual (pharmacological therapy) | Significant differences between groups for SAPS scores | High |
| Tao et al., 2015 | China | 86 | Cognitive rehabilitation | 30 min/session, 2 sessions/w, | Memory, attention, language, executive functions, coordination | Treatment as Usual, pharmacological | No significant effects on PANSS scores | |
| Yamanushi et al., 2024 | Japan | 15/15 | Cognitive remediation therapy, Rehacom | 60 min/session, | Attention/vigilance, working memory, verbal learning and memory, visual learning and | Treatment as Usual (psychopharmacological therapy) | Significant time × group interaction for (SANS) anhedonia/asociality scores (Rehacom: 21.57 ± 4.16 → 18.36 ± 4.80; control: 21.69 ± 3.84 → 21.23 ± 3.30, | Moderate |
| Ojeda et al., 2012 | Spain | 93 | Rehacop | 90 min/session, 3 sessions/w, 12 weeks | Attention, processing speed, memory, language, executive functions, social cognition | Occupational therapy | Significant difference between groups when controlling cognitive change in insight and CGI scores improved | High |
| Sánchez et al., 2014 | Spain | N = 92, 36/48 | Rehacop | 90 min/session, 3 sessions/w, | Attention, memory, processing speed, language, executive functions, social cognition | Treatment as Usual (psychopharmacological therapy) | Significant time × group interaction between groups for negative symptoms | Moderate |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSchizophrenia research and treatment · Functional Brain Connectivity Studies · Mental Health and Psychiatry
1. Introduction
Schizophrenia is a devastating disorder, imposing a heavy burden on patients, families, and society [1]. The introduction of antipsychotic agents brought forth a revolution in the treatment of the disease, succeeding in bringing many patients living in asylums back to the community [2]. Still, achieving recovery or even symptomatic remission remains elusive to this day, and even when remission is achieved, many patients experience residual or persisting symptoms, cognitive decline, and functional failure [3]. Cognitive deficits are a core characteristic of schizophrenia and notably resistant to treatment. They include deficits in working and verbal memory, processing speed, attention, executive function, and reasoning, among others [4]. Deficits in social cognition are also apparent and highly detrimental; they seriously interfere with the ability of schizophrenic patients to communicate effectively and achieve or maintain social communication [5]. Medication, including antipsychotics as well as novel agents (d-cycloserine, memantine, and anticholinesterase inhibitors represent some examples), have proven ineffective or minimally effective [6]. However, besides cognitive symptoms, other symptom domains also tend to persist and often show resistance to available pharmaceutical agents, creating serious distress in patients’ lives and even frustration for families and treating clinicians [7].
These symptoms include positive symptoms, such as delusions and hallucinations, negative symptoms, such as abulia, loss of interest, blunted affect, withdrawal, and anergia, mood symptoms, most usually depressive, and others. The latter cause serious distress, frustration, and suicidal thoughts or attempts in patients [8]. The situation is grim, and novel or additional therapies that can increase the therapeutic effect and outcome are more than welcome; their implementation is crucial and even necessary.
Cognitive remediation (CR) is a rehabilitative therapeutic procedure that takes advantage of the brain’s neuroplastic ability, essentially to increase the patient’s cognitive capacity and functional outcome. It has been practiced in a broad variety of medical conditions, beginning with traumatic brain injury, but it was quickly implemented in psychiatric disorders, including schizophrenia, for the treatment of cognitive deficits that are almost universally present in such patients [9].
Due to the important benefits of CR, this method has been included by the European Psychiatric Association in the treatment guidelines for cognitive deficits of schizophrenia [10]. Recent studies have shown a positive effect of CR on additional clinical symptoms, and it possibly represents an indispensable therapeutic modality for the management of patients with schizophrenia. The present review is a comprehensive overview of the efficacy of CR in treating clinical symptoms beyond the positive effects of medication and assists in increasing familiarity and confidence among clinicians for the benefit of their patients.
2. Materials and Methods
Literature Search
A comprehensive search was conducted in PubMed, Scopus, and Science Direct databases from inception to 14 July 2025. We used the following search string for all three databases screened for eligible articles: ((cognitive remediation) OR (cognitive rehabilitation) OR (cognitive training)) AND psychopathology OR delusions OR hallucinations OR negative OR depressive OR anxiety). Across databases, the search fields were title, abstract, and keywords. A search of the gray literature was not performed. Reference lists of relevant papers were searched manually for additional studies. Our aim was to provide data derived from original research. The following inclusion criteria were applied based on the PICO framework for systematic reviews. (1) Population: Samples consisting of patients with schizophrenia, diagnosed based on specific classification or operationalized criteria. (2) Intervention: An experimental group that underwent cognitive remediation to target specific cognitive deficits, whether computerized, paper-and-pencil, or otherwise. (3) Comparator: An RCT design where a control group and randomized allocation were utilized. The control group interventions included various treatments, such as pharmacotherapy, psychotherapy, or occupational therapy (a complete list of the control group interventions is presented in Table 1). (4) Outcome: Changes in cognitive and clinical symptoms assessed using relevant scales and explicitly reported. Exclusion criteria were as follows: (1) study designs or article types other than original, i.e., case reports, conference proceedings, reviews, meta-analyses, study protocols, (2) study designs other than randomized controlled trials, (3) articles published in languages other than English, and (4) not specified or unclear reporting of cognitive and clinical outcomes. Articles were excluded at the full-text stage if (1) samples consisted of patients with multiple disorders from the schizophrenia spectrum within a group, including schizoaffective disorder, (2) the control group was unsuitable as a comparator, mainly because of a cognitive remediation intervention being implemented, or (3) there was no mention of the preferred method of diagnosis confirmation (e.g., DSM-V).
This systematic review is registered with the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD 420251154674). The review was conducted according to the PRISMA guidelines for reporting systematic reviews [11]. Abstract and full-text screening was conducted by two independent reviewers (MS and PS) using the Cadima evidence synthesis tool and database [12]; disagreement was resolved by consensus or by consulting with the supervisor of the study (LM). The flow diagram of the screening and selection of studies is presented in Figure 1.
Data from included studies were extracted and organized into tables summarizing study characteristics, interventions, outcomes, and risk of bias. Supplementary Table S3 presents the effect size indices used—η^2^, ηp^2^, d, ES, total b—in a comprehensive manner to facilitate understanding. The methodological quality of the studies was assessed using the revised JBI critical appraisal tool for the risk of bias of RCTs [13] (Supplementary Tables S1 and S2). Each study was evaluated across 13 criteria covering different sources of methodological bias. All included records were assessed independently by two reviewers (MS and PS); disagreement was resolved through consensus. A composite rating for every study was calculated as follows: studies meeting >70% of the criteria were rated “low” risk, those meeting 50–70% were rated “moderate” risk, and studies meeting <50% were rated as having a “high” risk of bias. A detailed breakdown of each study’s criterion rating is provided in Supplementary Table S4.
No attempts were made to retrieve missing data from the study authors. We considered missing information to reflect the authors’ reporting decisions; therefore, only the data available in the published reports were extracted.
3. Results
3.1. Overview
After database searches and screening, a total of 35 studies were included in the analysis (Table 1). Most studies were of moderate methodological quality; however, seven of them had low risk of bias [14,15,16,17,18,19,20]. Sample sizes ranged between 11 [21] and 270 [17], with the majority recruiting less than 100 patients. Interventions were diverse, including computerized or paper-and-pencil training, individually or in groups, virtual reality, and social cognition or metacognition components, whereas control groups received Treatment as Usual (TAU) with medication only or various types of psychosocial therapies, such as supportive therapy, music and dancing therapy, occupational rehabilitation, and others. Most studies explored dimensions of psychopathology by applying the Positive and Negative Symptoms Scale (PANSS), while some focused on depressive symptoms or anxiety. About one-third [17,21,22,23,24,25,26,27,28,29,30,31,32] examined clinical effects as a secondary outcome. Of the studies, 13 reported measures of effect sizes [16,22,25,28,30,33,34,35,36,37,38,39,40].
3.2. Specific Symptom Outcomes
Positive symptoms were assessed with the use of the PANSS (positive subscale) or, rarely, the Brief Psychiatric Rating Scale (BPRS), the Present State Examination (PSE), or the Scale for the Assessment of Positive Symptoms (SAPS). Of the studies that conducted these assessments (n = 34), only four [22,36,41,42] demonstrated a significantly superior effect of cognitive remediation over TAU or other rehabilitation (art therapy, physical training, occupational therapies) [41]. Only one [41] reported an effect size, which was found to be small. The sample of two studies consisted of inpatients, acutely ill patients [22], or patients in rehabilitation centers [41]. Duration of treatment was 4 to 24 weeks.
On the contrary, statistically significant improvements in negative symptoms were more readily found and are reported by 12 studies. Of those, five report effect sizes, large [25,27,28] or medium to large [30,38], in samples including outpatients, remitted inpatients, or both. Specifically, Peña et al. and Yamanushi et al. reported improvements in social amotivation and anhedonia/asociality with medium to large effect sizes [30,39]. Duration of studies was between 6 and 24 weeks.
Five studies also report significant superiority of cognitive remediation interventions vs. control conditions on the general PANSS subscale, with small, medium, or large effect sizes [25,29,35,41,46], and another five for total PANSS scores [16,20,36,41,46]. In the study by Penadés et al. [15], which compared cognitive remediation vs. CBT in a sample of chronic outpatients, CBT outperformed cognitive remediation in the general PANSS subscale, while CR was superior in the cognitive factor of PANSS. Positive results are also reported for disorganization [28,36,38,40], with large sizes [28], for excitement, with medium sizes [30,40], and for emotional distress, with a large effect size. Fekete et al. investigated whether baseline symptom severity had any impact on the degree of symptomatic improvement; they found that a PANSS score of >75 was predictive of greater improvements of symptoms following cognitive rehabilitation [36].
Insight was explored by Ojeda et al. [48], where a significantly superior effect over occupational therapy was reported. Volition was found to respond better to CR vs. TAU, according to Li et al. [35].
Nine studies focused on other symptoms of schizophrenia. Regarding depression, significantly superior results were reported by five studies [19,33,34,37,46], with a small to moderate effect size. Two studies yielded negative outcomes [14,43]. In the study by Penadés et al. [15], CBT proved superior to CR for the treatment of depressive symptoms. As for anxiety, the study by Fathi et al. [19] found better performance of CR on the stress subscale of DASS (DASS-S], but not anxiety. Also, Gharaeipour and Scott [43] obtained negative results regarding anxiety.
Only two studies reported long-term follow-up assessments at 3 or 6 months and showed that therapeutic effects seem to persist [19,36].
4. Discussion
Although cognitive remediation has well-documented effects on cognitive deficits of patients with schizophrenia, results for other symptoms seem promising, yet not unequivocally. In the present review, the existing evidence is mixed, with positive and negative results for various aspects of psychopathology. There are several reasons that could lead to this inconsistency. A significant portion of the studies included in the present systematic review had one or multiple methodological issues. Information regarding blinding, group allocation, or inter–rater reliability was often omitted from the studies. Furthermore, the exclusion of articles in other languages instead of English could have excluded relevant findings. Patient samples are mostly rather small, and studies present significant heterogeneity in terms of setting, including inpatient, outpatient in the community or in rehabilitation, and day centers, phase of illness, whether acute, chronic, remitted, or early course, type and components of intervention, dosing, including number of sessions and duration of treatment, and control conditions, including Treatment as Usual or treatments other than cognitive remediation. Although a meta-analysis could possibly clarify or reduce the confusion, the degree of heterogeneity would compromise the comparability of the studies and the feasibility of meta-analytic processing. It is expected that effects on patients with different characteristics would vary. It is probable that in situations where positive symptoms are severe, there is a larger deviation of scale scores than in a remitted condition and a larger range for putative improvement, which is more promptly demonstrable by the statistical analyses. This could be the case for the positive results of the studies on acutely ill patients, contrary to most studies, which yield negative results. In stable subjects, on the other hand, marked negative symptoms with minimal scores on positive subscales are the most common presentation; hence, it is for negative symptoms that patients would experience more benefits. In the same line stand the findings of Fekete et al. [36], where total scores of PANSS > 75 are associated with significantly greater improvements from the intervention. Given that a large percentage of patients are only partially remitted or refractory despite adequate trials of antipsychotic medication, the therapeutic potential of cognitive remediation becomes particularly important.
Although the effectiveness of the intervention cannot be definitively ascertained at this point, given that effect sizes of the improvements were in many cases large or medium and follow-up assessments demonstrated maintenance of the therapeutic benefits, this is very important for the substantiation of the efficacy of cognitive rehabilitation methods. Furthermore, investigation of the neurobiological processes that underly the therapeutic effects and mediate the transfer of the cognitive gains to other areas of clinical state and functioning remains crucial. Some studies have investigated neurobiological and neuroimaging aspects of cognitive rehabilitation that could be relevant to this matter. Increased activation and functional connectivity after cognitive remediation have been reported in multiple regions, such as the prefrontal cortex and thalamic regions [49,50]. Sampedro et al. [51], based on the sample of patients they examined in their previous study [28] (which is included in the present review), found greater cortical thickness in the right temporal lobe (right temporal pole, inferior temporal gyrus, middle temporal gyrus, superior temporal gyrus, and fusiform gyrus) at post-treatment compared to pre-treatment in the REHACOP group but not in the active control group. These are areas especially pertinent to the pathophysiology of positive and negative schizophrenic symptoms. More specifically, dysfunction in temporal areas has been associated with auditory hallucinations and disruption of fronto-striato-thalamic circuits with delusions [52,53]. Negative symptoms are thought to be related to the hypofunction of frontal areas, including the anterior cingulate cortex [54]. Frontal lobe dysfunction has been identified as a neural correlate of depression [55]. Furthermore, enhanced self-esteem is related to the newly achieved functional gains, which adds to the patients’ positive affect [56].
A groundbreaking line of research focuses on the glymphatic system’s function in relation to psychosis. This system is a pathway based on the astrocytes, and it allows for the exchange of cerebrospinal fluid with interstitial fluid through a paravascular network formed by the astrocytes, with aquaporin-4 (AQP4) having a central role. Normally, this leads to the removal of solute metabolic waste from the cerebrospinal fluid to the lymphatic system and thus to a clean and stable brain microenvironment [57,58]. Intact sleep, particularly delta-rich slow-wave (N3) sleep, is crucial for optimal system function [59].
It has been recently indicated that people with psychosis, even at an early stage of illness, show compromised function of the glymphatic system compared to healthy controls [60], and such a dysfunction is correlated with cognitive impairment [61] and psychotic symptoms [62].
Could this action work both ways? More specifically, could the amelioration of cognitive functioning through cognitive remediation help normalize glymphatic function? Although currently this is just a hypothesis, there are some supporting recent findings. Enhanced cognitive function seems to improve resting-state functional connectivity [63] and relieve sleep problems [64], which could result in enhancing glymphatic system function. This, in turn, would allow for more efficient removal of metabolic waste, a stable brain microenvironment, and improvement of the status of neuroglia and astrocytes, with further empowerment of large-scale brain circuits. Because of these changes, psychotic and cognitive symptoms might be further reduced, establishing a virtuous circle of clinical improvement.
In view of the above, many issues remain to be elucidated. The preceding neurobiological explanation of the therapeutic effects of cognitive remediation, although aligned with current knowledge on brain function, remains only hypothetical and fragmentary, calling for robust, extensive research. Questions regarding optimal elements of the intervention and the duration, dosing, and timing of the therapy must be answered. Documentation of the cost-effectiveness of the method is another critical issue that would facilitate the broader delivery of cognitive rehabilitation. To this end, there is a need for more studies with low risk of bias and larger samples of patients. Standardized outcome measures and long-term follow-up would further strengthen evidence around the effectiveness and the persistence of the therapeutic effects. The present data indicate that a careful recommendation of this intervention can be offered alongside treatment as usual while awaiting more definitive data.
5. Limitations
Limitations of the present study include the fact that the literature search was conducted using three databases only. This might have led to the omission of studies available through other databases, such as Embase, PsycINFO, Web of Science, and others. If included, they might contribute to findings that would enrich our results and further increase the robustness of the present study. The same limitation pertains to the exclusion of articles written in languages other than English. Articles published in languages other than English were not included, and therefore certain information may be missed.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Jauhar S. Johnstone M. Mc Kenna P.J. Schizophrenia Lancet 202239947348610.1016/S 0140-6736(21)01730-X 35093231 · doi ↗ · pubmed ↗
- 2Leucht S. Priller J. Davis J.M. Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application Am. J. Psychiatry 202418186587810.1176/appi.ajp.2024073839350614 · doi ↗ · pubmed ↗
- 3Vita A. Barlati S. Recovery from Schizophrenia: Is It Possible?Curr. Opin. Psychiatry 20183124625510.1097/YCO.000000000000040729474266 · doi ↗ · pubmed ↗
- 4Takeda T. Umehara H. Matsumoto Y. Yoshida T. Nakataki M. Numata S. Schizophrenia and Cognitive Dysfunction J. Med. Investig.20247120520910.2152/jmi.71.20539462553 · doi ↗ · pubmed ↗
- 5Dziwota E. Stepulak M.Z. Włoszczak-Szubzda A. Olajossy M. Social Functioning and the Quality of Life of Patients Diagnosed with Schizophrenia Ann. Agric. Environ. Med.201825505510.5604/12321966.123356629575877 · doi ↗ · pubmed ↗
- 6Javitt D.C. Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment Annu. Rev. Pharmacol. Toxicol.20236311914110.1146/annurev-pharmtox-051921-09325036151052 · doi ↗ · pubmed ↗
- 7Rangaswamy T. Greeshma M. Course and Outcome of Schizophrenia Int. Rev. Psychiatry 20122441742210.3109/09540261.2012.70797323057978 · doi ↗ · pubmed ↗
- 8Diniz E. Fonseca L. Rocha D. Trevizol A. Cerqueira R. Ortiz B. Brunoni A. Bressan R. Correll C. Gadelha A. Treatment Resistance in Schizophrenia: A Meta-Analysis of Prevalence and Correlates Braz. J. Psychiatry 20234544845810.47626/1516-4446-2023-312637718484 PMC 10894625 · doi ↗ · pubmed ↗
